Effect of obesity on cyclosporine disposition.

Transplantation

Division of Clinical Research, Fred Hutchinson Cancer Research Center, School of Pharmacy, University of Washington, Seattle.

Published: March 1988

Download full-text PDF

Source
http://dx.doi.org/10.1097/00007890-198803000-00029DOI Listing

Publication Analysis

Top Keywords

obesity cyclosporine
4
cyclosporine disposition
4
obesity
1
disposition
1

Similar Publications

The cardiometabolic safety of dupilumab in atopic dermatitis: A global large-scale cohort study.

Arch Dermatol Res

January 2025

Lűbeck Institute of Experimental Dermatology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.

Background: A low risk of cardiovascular and metabolic outcomes was found in the randomized clinical trials of dupilumab in atopic dermatitis (AD). Dupilumab-associated real-life long-term cardiometabolic risk relative to other systemic agents is yet to be precisely investigated.

Objective: To assess the risk of cardiometabolic outcomes in patients with AD treated with dupilumab relative to those treated with methotrexate and cyclosporine.

View Article and Find Full Text PDF

Background: Calcineurin inhibitors and mammalian target of rapamycin (mTOR) inhibitors are essential for maintaining transplanted organs. However, determining the appropriate dosage and predicting blood concentrations of these drugs based solely on net body weight may be inadequate. Previous studies have presented contradictory results regarding the impact of obesity on drug concentrations and transplant success.

View Article and Find Full Text PDF
Article Synopsis
  • PASH syndrome is an autoimmune condition that causes skin problems like acne and painful sores, which get worse over time.
  • A 36-year-old man had severe symptoms including skin ulcers and struggled to find effective treatments until he improved using Infliximab.
  • Treating PASH syndrome is tricky because it can be linked to other health issues, and doctors need to try different therapies to see what works best for each patient.
View Article and Find Full Text PDF

Recent advancements in immunology and islet biology have unveiled remarkable prospects for the postponement of Type 1 diabetes (T1D) through the strategic modulation of the immune system. In this Perspective, we discuss the pharmaceutical strides achieved, traversing from pre-clinical validation to the execution of impactful clinical trials. We begin with the initial investigations involving cyclosporine and glucocorticoids in rodent models, such as the non-obese diabetic (NOD) mouse, which guided early clinical trials.

View Article and Find Full Text PDF

Clinical Characteristics and Disease Burden of Patients with Moderate-to-Severe Generalized Pustular Psoriasis Flares in Taiwan.

Dermatol Ther (Heidelb)

August 2024

Department of Dermatology, Drug Hypersensitivity, Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei and Keelung, No. 5, Fuxing St, Guishan District, Taoyuan, 333, Taiwan.

Article Synopsis
  • * A retrospective analysis included 34 adult patients with 81 moderate-to-severe GPP flares between 2008 and 2021, revealing a high prevalence of IL36RN mutations (71.4%) in those tested and various systemic treatments being employed.
  • * Complications like arthritis and skin infections were common post-flare, but no fatalities occurred; factors like prior smoking and existing hepatic disease were linked to increased GPP flare rates according to multivariate analysis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!